SynthesisIndian heart journal2018
The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.
Synthesis in Indian heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Predicting the no-reflow phenomenon in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a systematic review of clinical prediction models.Therapeutic advances in cardiovascular diseasePooled it
- The Gene Polymorphism of Angiotensin-Converting Enzyme Intron Deletion and Angiotensin-Converting Enzyme G2350A in Patients With Left Ventricular Hypertrophy: A Meta-analysis.Indian heart journalPooled it
- Clinical and Angiographic Predictors of No-Reflow and Its Impact on Outcomes in ST-Elevation Myocardial Infarction: A Retrospective Study.Clinical cardiology · 2026Article
- Nanocarrier-Based Therapeutic Strategies in Myocardial Ischemia-Reperfusion Injury: A Systematic Review of Preclinical Evidence.Biomedicines · 2026Review
- Endothelial Activation and Stress Index (EASIX) as a novel index associated with no-reflow phenomenon in STEMI: a bi-center retrospective study.BMC cardiovascular disorders · 2026Article
- The Naples Prognostic Score May Predict No Reflow in Patients Undergoing Percutaneous Coronary Intervention for Saphenous Vein Graft Stenosis.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Platelet-derived growth factor-BB is a novel inflammatory biomarker of no-reflow in STEMI patients treated with primary PCI.Journal of thrombosis and thrombolysis · 2026Observational
- Admission EASIX Score Predicts Coronary No-Reflow and In-Hospital Mortality in STEMI Patients Undergoing Primary PCI.Journal of clinical medicine · 2026Article
- A practical approach to the management of percutaneous coronary intervention complications.Frontiers in cardiovascular medicine · 2026Review
- Reconsidering the CHA2DS2-VASc Score for No-Reflow Risk Stratification after Percutaneous Coronary Intervention.Arquivos brasileiros de cardiologia · 2026Article
- Article
- Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial.European heart journal open · 2025Article
- Novel insights into no-reflow post-PCI: The predictive value of coronary sinus hemodynamics.Global cardiology science & practice · 2025Article
- How an Aggressive Treatment of No-reflow Phenomenon in Primary Percutaneous Coronary Intervention with High Thrombus Burden can Achieve a Grade III TIMI-flow: A Case Report.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Article
- Changes and Diagnostic Significance of miR-542-3p Expression in Patients with Myocardial Infarction.Molecular biotechnology · 2025Article
- Advances in Pathophysiology and Novel Therapeutic Strategies for Coronary No-Reflow Phenomenon.Biomedicines · 2025Review
- Thrombus-Demarcated Stenting with Dual-Contrast Imaging: A Novel Approach for Late-ST-Segment Elevation Myocardial Infarction with Unsuccessful Predilatation.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Article
- The Predictive Value of ALBI Score for No-Reflow in Non-ST Elevation Acute Coronary Syndrome.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the no reflow risk factors after percutaneous coronary intervention in ST elevation myocardial infarction patients.
methodSample size, mean±standard deviation (SD) or frequencies (percent) of normal and no reflow groups were extracted from each study.
resultsOf 27 retrospective and prospective studies, we found that increasing risks of no reflow were associated with advanced age, male, family history of coronary artery disease, smoking, diabetes mellitus, hypertension, delayed reperfusion, killip class ≥2, elevated blood glucose, increased creatinine, elevated creatine kinase (CK), higher heart rate, decreased left ventricular ejection fraction (LVEF), collateral flow ≤1, longer lesion length, multivessel disease, reference luminal diameter, initial thrombolysis in myocardial infarction (TIMI) flow, and high thrombus burden. Moreover, initial TIMI flow ≤1 and high thrombus burden had the greater impact on no reflow (OR95%CI=3.83 [2.77-5.29], p<0.0001 and 3.69 [2.39-5.68], p<0.0001, respectively).
conclusionOur meta-analysis reveals that initial TIMI flow ≤1 and high thrombus burden are the most impacted no reflow risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.